SCHEMBL22096096

SCHEMBL22096096

CC(C)c1ccnc2[nH]cc(-c3ccccc3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 9/20 0.50
ROCK1 Q13464 9/20 0.48
PRKACA P17612 7/20 0.48
CDK5 Q00535 7/20 0.48
DYRK1A Q13627 6/20 0.48
PRKD3 O94806 6/20 0.48
MAP4K4 O95819 6/20 0.48
CLK2 P49760 6/20 0.48
MAP4K2 Q12851 6/20 0.48
GSK3A P49840 6/20 0.48
GSK3B P49841 6/20 0.48
CDK8 P49336 5/20 0.48
NTRK1 P04629 4/20 0.48
TAOK1 Q7L7X3 4/20 0.48
CLK4 Q9HAZ1 4/20 0.48
NTRK2 Q16620 4/20 0.48
NTRK3 Q16288 4/20 0.48
PAK4 O96013 4/20 0.48
MAP2K1 Q02750 4/20 0.48
CAMK2A Q9UQM7 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22923901 0.80 LRRK2 (0.54) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL27010942 0.79 IRAK4 (0.43) LRRK2ROCK1CDK5ROCK2JAK2
SCHEMBL26930189 0.77 CAMKK2 (0.44) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL31735139 0.77 CAMKK2 (0.44) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL29952060 0.76 LRRK2 (0.50) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL23133692 0.76 CCNK (0.43) LRRK2ROCK1CDK5DYRK1AMAP4K4
SCHEMBL22304206 0.76 JAK2 (0.38) LRRK2ROCK1CDK5RPS6KA3ROCK2
SCHEMBL31735024 0.74 LRRK2 (0.44) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL26953091 0.74 LRRK2 (0.44) LRRK2ROCK1PRKACACDK5DYRK1A
SCHEMBL22304229 0.74 LRRK2 (0.45) LRRK2ROCK1PRKACACDK5PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof NRAS, AXL, ABL1 LRRK2 597/4885ROCK1 322/4885PRKACA 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.